Atezolizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Atezolizumab (ncit:C106250)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel